Cargando…

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Derenzini, E, Lemoine, M, Buglio, D, Katayama, H, Ji, Y, Davis, R E, Sen, S, Younes, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219443/ http://dx.doi.org/10.1038/bcj.2014.57

Ejemplares similares

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2011)

JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B‐Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation
por: Lu, Z., et al.
Publicado: (2017)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo
por: Yan, Shuang, et al.
Publicado: (2013)

Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480
por: Gudernova, Iva, et al.
Publicado: (2017)

AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines
por: Couto, Joana P., et al.
Publicado: (2012)

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
por: Derenzini, Enrico, et al.
Publicado: (2011)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells
por: Maenhout, Sarah K., et al.
Publicado: (2014)

Tumor necrosis factor-308 polymorphism with the risk and prognosis of non-Hodgkin lymphomas: a meta-analysis study [Corrigendum]
Publicado: (2016)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
Publicado: (2022)

Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
por: Diaz, Tania, et al.
Publicado: (2011)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
por: Van Den Neste, Eric, et al.
Publicado: (2018)

Dental Science in 1480—As Expounded by Peter De Largelata
por: Trueman, William H.
Publicado: (1900)

Dental Science in 1480, as Expounded by Peter De Largelata
por: Trueman, William H.
Publicado: (1899)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas
por: Kreuz, S., et al.
Publicado: (2015)

Catalogue of Medical Books in Manchester University Library, 1480–1700
Publicado: (1974)

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Publicado: (2017)

Corrigendum to “Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages” [Heliyon 9(3) (March 2023) e14272]
por: Hu, Weimin, et al.
Publicado: (2023)

JAK inhibitors for refractory lymphoma
por: Kimura, Hiroshi
Publicado: (2018)

P1480: CLINICAL AND GENETIC STUDY OF HEREDITARY SPHEROCYTOSIS IN THE SPANISH POPULATION.
por: Castilla, Lucia, et al.
Publicado: (2023)

HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells
por: Schoof, Nils, et al.
Publicado: (2009)

Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
por: Boykin, C, et al.
Publicado: (2012)

Corrigendum to “Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells”
por: Jung, Ji Hoon, et al.
Publicado: (2018)

Corrigendum to “JAK2/STAT3 Pathway Was Associated with the Protective Effects of IL-22 on Aortic Dissection with Acute Lung Injury”
por: Ren, Wei, et al.
Publicado: (2019)

Correction to ‘Gotree/Goalign: toolkit and Go API to facilitate the development of phylogenetic workflows’
por: Lemoine, Frédéric, et al.
Publicado: (2021)

La filosofía del amor en la literatura española 1480-1680 /
por: Parker, Alexander A. (Alexander Augustine), 1908-1989
Publicado: (1986)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

AZD-1222: Vaccine associated hypermetabolic abdominal and cervical lymph nodes mimicking Hodgkin lymphoma relapse: case report
Publicado: (2022)

Corrigendum to “miR-375 Inhibits the Proliferation and Invasion of Nasopharyngeal Carcinoma Cells by Suppressing PDK1”
por: Jia-yuan, Xu, et al.
Publicado: (2020)

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression
por: Oki, Y, et al.
Publicado: (2014)

Traditional Chinese Medicine Astragalus Polysaccharide Enhanced Antitumor Effects of the Angiogenesis Inhibitor Apatinib in Pancreatic Cancer Cells on Proliferation, Invasiveness, and Apoptosis [Corrigendum]
Publicado: (2022)

Corrigendum to “Radiological Features of Gastrointestinal Lymphoma”
por: Lo Re, Giuseppe, et al.
Publicado: (2016)

Corrigendum to “Salvianolic Acid B Protects Intervertebral Discs from Oxidative Stress-Induced Degeneration via Activation of the JAK2/STAT3 Signaling Pathway”
por: Dai, Shouqian, et al.
Publicado: (2022)

Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics
por: Calabretta, Eleonora, et al.
Publicado: (2022)

The Voice The Garden Spanish Songs And Motets, 1480-1550 Gothic Voices/ Christopher Page

Repeated Intravenous Administration of Silica Nanoparticles Induces Pulmonary Inflammation and Collagen Accumulation via JAK2/STAT3 and TGF-β/Smad3 Pathways in vivo [Corrigendum]
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ps1f8jllpoqqvdra7s5v061hm9